
For surveillance of patients with cirrhosis, a novel blood test found more hepatocellular carcinoma at an early stage than ultrasound, according to a modeling study presented at the 2022 ASCO Gastrointestinal Cancers Symposium.
Clinical guidelines recommend ultrasound with or without the serum biomarker alpha-fetoprotein (AFP) for the surveillance of individuals at risk for HCC, but only about one-fourth of patients adhere to this practice, according to investigator